Lonza Expands UK Mammalian Production

Swiss fine and specialty chemicals producer Lonza has expanded its mammalian production capacity to meet increased demand for biopharmaceutical development and clinical manufacturing services.

Two 1,000 liter single-use bioreactors have been added to its site in Slough, UK, the company’s center of excellent for development and clinical supply, significantly increasing capacity.

Lonza said the new reactors, equipped with controllers that enable parallel operations and expanded process capabilities with flexible operating scales and bioreactor types, complement existing single-use equipment for both seed train systems and downstream processing, including chromatography, filtration and ultrafiltration unit operations.

The company added that the technologies support its ability to accommodate a variety of customer projects and processes across scales and clinical phases.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read